Reyon Pharmaceutical Co Ltd (102460.KS) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · South Korea · ISIN KR7102460003
Reyon Pharmaceutical Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 148.30 bn KRW | 145.93 bn KRW |
| Gross profit | 72.79 bn KRW | 38.23 bn KRW |
| Operating income | -554.86 m KRW | -30.69 bn KRW |
| EBIT | 6.42 bn KRW | -11.41 bn KRW |
| Net income | 4.15 bn KRW | -29.63 bn KRW |
| Diluted EPS – continuing operations | 226.34 KRW | -1,615.68 KRW |
Full history since 2008, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Reyon Pharmaceutical Co Ltd
REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; migraine drugs; miscellaneous cardiovascular system drugs; neuromuscular disorder related drugs; nootropics and neurotonics; NSAIDs; respiratory stimulants; skeletal muscle relaxants; and vasodilators. It also develops VM202RY, a vascular neurological disease, etc. gene therapy drug, which is in Phase II clinical trial to treat coronary artery disease, chronic non-healing diabetic/ischemic ulcers, diabetic neuropathy, and amyotrophic lateral sclerosis; VM206RY, anti-cancer gene therapy, which is under Phase I clinical trials for treatment of breast cancer; RY103 [NS101], therapeutics antibody for Alzheimer; and RY104, a gene therapy to treat age-related macular degeneration, as well as BIO-101, a HBV gene vaccine, which is in preclinical studies for hepatitis B; RY105, gene therapy to treat liver fibrosis; GB102, for treatment of chronic kidney and coronary artery disease; RY110 which is an iPSC-derived NK cell therapy for solid tumors; RY108, an antifungal drug which is under preclinical study. In addition, the company engages in the research of RY106/RY107, a mRNA-based virus vaccine and gene therapy for anti-virus and rare genetic diseases; and RY109 which is a pDNA-based cancer vaccine for treatment of Ovarian cancer. REYON Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Seoul, South Korea.
More stocks
- Schloss Wachenheim (SWA.DE)
- Woojin (105840.KS)
- Adagene Inc (ADAG)
- 6K Additive Inc (6KA.AX)
- Cheng Fwa Industrial Ltd (5426.TWO)
- Centaurus Metals Ltd (CTM.AX)
- Bright Sheland International Co Ltd (4556.TWO)
- Ever Fortune.AI Co. Ltd. (6841.TWO)
- KVH INDUSTRIES INC \DE\ (KVHI)
- CONPET SA (COTE.RO)
- Pyrum Innovations (PYR.DE)
- ReposiTrak, Inc. (TRAK)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.